Surgical methods of treatment of chronic heart failure and their place in modern clinical recommendations

Abstract

This review discusses a number of aspects of surgical methods for treating severe chronic heart failure: resynchronizing therapy, mechanical circulatory support systems, and heart transplantation. Surgical methods for the treatment of heart failure are a rapidly developing field of modern cardiology and cardiac surgery. The main surgical method of treatment was and remains orthotopic transplantation of a donor heart. The advent of implantable systems has affected the problem of heart transplantation. Over the past decade, the use of mechanical circulatory support systems has grown significantly. At the moment, there are 3 main directions: creating devices for auxiliary blood circulation, various modes and methods of electrical stimulation of the myocardium, creating devices that mechanically remodel the heart chambers (left ventricle). All of these directions to some extent (depending on the evidence base) have found their place in modern recommendations for the treatment of chronic heart failure. The use of mechanical left ventricular remodeling shows good results in patients suffering from symptomatic heart failure, which leads to a significant and persistent decrease in the volume of the left ventricle and improvement of its function, symptoms and quality of life. Despite the fact that at the moment the geography and prevalence of their use is small, the number of implanted devices will only grow. Thus, given the need for frequent hospitalizations and high treatment costs, it is necessary to improve modern methods of surgical treatment of severe and terminal heart failure, make them more accessible, which will affect the duration and quality of life of these patients.

Keywords

chronic heart failure / surgical methods of treatment / resynchronizing therapy / cardioverter-defibrillator / heart transplantation / modulation of cardiac contractility

References

[1] Колоскова, Н.Н. Терминальная сердечная недостаточность. Отбор пациентов для постановки в «лист ожидания» на трансплантацию сердца: дис. … канд. мед. наук. – М., 2011. – 119 c.

[2] Логинов, И.В. Значение организационных факторов в преодолении дефицита донорских органов / И.В. Логинов, Н.В. Кечаева, О.Н. Резник // Вестн. трансплантологии. – 2011. – № 13 (1). – C. 100–107.

[3] Мареев, В.Ю. Клинические рекомендации. Хроническая сердечная недостаточность (ХСН) / В.Ю. Мареев [и др.] // Сердечная недостаточность. – 2017. – № 18 (1). – С. 3–40.

[4] Ревишвили, А.Ш. Клинические рекомендации по проведению электрофизиологических исследований, катетерной аблации и применению имплантируемых антиаритмических устройств / А.Ш. Ревишвили [и др.]. –М., 2011. – 518 с.

[5] Abraham, W.T. A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation / W.T. Abraham [et al.] // JACC Heart Fail. – 2018. – Vol. 6. – P. 874–883.

[6] Arshad, A. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial / A. Arshad [et al.] // J. Am. Coll. Cardiol. – 2011. – Vol. 57. – P. 813–820.

[7] Beshai, J.F. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes / J.F. Beshai [et al.] // N. Engl. J. Med. – 2007. – Vol. 13. – P. 2461–2471.

[8] Cazeau, S. Effects of multisitebiventricular pacing in patients with heart failure and intraventricular conduction delay / S. Cazeau [et al.] // N. Engl. J. Med. – 2001. – Vol. 12. – P. 873–880.

[9] Christie, J.D. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report-2010 / J.D. Christie [et al.] // J. Heart Lung Transplant. – 2010. – Vol. 29. – P. 1104–1118.

[10] Chung, E.S. Results of the predictors of response to CRT (PROSPECT) trial / E.S. Chung [et al.] // Circulation. – 2008. – Vol. 117. – P. 2608–2616.

[11] Daubert, J.C. Permanent left ventricular pacing with transvenous leads inserted into the coronary veins / J.C. Daubert [et al.] // Pacing Clin. Electrophysiol. – 1998. – Vol. 2. – P. 239–245.

[12] Goldenberg, I. Reduction of the risk of recurring heart failure events with cardiac resynchronization therapy / I. Goldenberg [et al.] // J. Am. Coll. Cardiol. – 2011. – Vol. 58. – P. 729–737.

[13] Hsu, J.C. Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome / J.C. Hsu [et al.] // J. Am. Coll. Cardiol. – 2012. – Vol. 59. – P. 2366–2373.

[14] Hunt, S.A. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation / S.A. Hunt [et al.] // Circulation. – 2009. – Vol. 119 (14). – P. 391–479.

[15] Jencks, S.F. Rehospitalizations among patients in the Medicare fee-for-service program / S.F. Jencks, M.V. Williams, E.A. Coleman // N. Engl. J. Med. – 2009. – Vol. 360. – P. 1418–1428.

[16] Kittleson, M.M. Cardiac Transplantation: Current Outcomes and Contemporary Controversies / M.M. Kittleson, J.A. Kobashigawa // JACC: Heart Failure. – 2017. – Vol. 5 (12). – P. 857–868.

[17] Klein, P. Less invasive ventricular reconstruction for ischemic heart failure / P. Klein [et al.] // Eur. J. Heart Fail. – 2019. – Vol. 21(12). – P. 1638–1650.

[18] Kоber, L. DANISH Investigators. Defibrillator implantation in patients with nonischemic systolic heart failure / L. Kоber [et al.] // N. Engl. J. Med. – 2016. – Vol. 375. – P. 1221–1230.

[19] Mehra, M.R. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update / M.R. Mehra [et al.] // J. Heart Lung Transplant. – 2016. – Vol. 35. – P. 1–23.

[20] Mehra, M.R. A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure / M.R. Mehra [et al.] //. N. Engl. J. Med. – 2017. – Vol. 376 (5). – P. 440–450.

[21] Miller, L.W. Use of a continuous-flow device in patients awaiting heart transplantation / L.W. Miller [et al.] // N. Engl. J. Med. – 2007. – Vol. 357. – P. 885–896.

[22] Obadia, J.F. The MITRA-FR study: design and rationale of a randomised study of percutaneous mitral valve repair compared with optimal medical management alone for severe secondary mitral regurgitation / J.F. Obadia [et al.] // EuroIntervention. – 2015. – Vol. 10. – P. 1354–1360.

[23] Okamura, H. Up-to-date cardiac resynchronization therapy / H. Okamura // J. Gen. Fam. Med. – 2017. – Vol. 18 (5). – P. 195–199.

[24] Olgin, J.E. VEST Investigators. Wearable cardioverter-defibrillator after myocardial infarction / J.E. Olgin [et al.] // N. Engl. J. Med. – 2018. – Vol. 379. – P. 1205–1215.

[25] Ponikowski, P. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC / P. Ponikowski [et al.] // Eur. J. Heart Fail. – 2016. – Vol. 18. – P. 891–975.

[26] Roger, V.L. Heart disease and stroke statistics: 2012 update: a report from the American Heart Association / V.L. Roger [et al.] // Circulation. – 2012. – Vol. 125. – P. 188–179.

[27] Schulze, P.C. Preoperative assessment of high risk candidates to predict survival following heart transplantation / P.C. Schulze [et al.] // Circ. Heart Fail. – 2013. – Vol. 15. – P. 121–125.

[28] Smith, S.A. Device therapy in advanced heart failure: what to put in and what to turn off. Remote telemonitoring and implantable hemodynamic devices for advanced heart failure monitoring in the ambulatory setting and the evolving role of cardiac resynchronization therapy / S.A. Smith, W.T. Abraham // Congest. Heart Fail. – 2011. – Vol. 17. – P. 220–226.

[29] Starling, R.C. ROADMAP Study Investigators. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: the ROADMAP study 2-year results / R.C. Starling [et al.] // JACC Heart Fail. – 2017. – Vol. 5. – P. 518–527.

[30] Stehlik, J. The Registry of the International Society for Heart and Lung Transplantation: twenty-eighth Adult Heart Transplant Report-2011 / J. Stehlik [et al.] // J. Heart Lung Transplant. – 2011. – Vol. 30 (10). – P. 1078–1094.

[31] Trivedi, J.R. Survival on the heart transplant waiting list: impact of continuous flow left ventricular assist device as bridge to transplant / J.R. Trivedi [et al.] // Ann. Thorac. Surg. – 2014. – Vol. 98. – P. 830–834.

[32] Ukkonen, H. Effect of cardiac resynchronization on myocardial efficiency and regional oxidative metabolism / H. Ukkonen [et al.] // Circulation. – 2003. – Vol. 107. – P. 28–31.

[33] Xu, Y.Z. The modulating effects of cardiac resynchronization therapy on myocardial metabolism in heart failure / Y.Z. Xu [et al.] // Pacing Clin. Electrophysiol. – 2016. – Vol. 39 (12). – P. 1404–1409.

[34] Xu, Z. Can pulmonary vascular resistance predict response to cardiac resynchronization therapy in patients with heart failure / Z. Xu [et al.] // Pacing Clin. Electrophysiol. – 2015. – Vol. 38 (10). – P. 1210–1216.

[35] Yancy, C.W. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines / C.W. Yancy [et al.] // J. Am. Coll. Cardiol. – 2013. – Vol. 62 (16). – P. 147–239.

[36] Yu, C.M. Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy / C.M. Yu [et al.] // Circulation. – 2005. – Vol. 112. – P. 1580–1586.

RIGHTS & PERMISSIONS

Kotsoeva O.T., Koltsov A.V., Tyrenko V.V., Ialovets A.A.